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Glutamine is one of the conditionally essential free
amino acids with multiple biological functions. Its
supplementation to parenteral nutrition has been
widely used for the management of complications in
intensive care. However, controversial clinical reports
have generated reluctance in the use of this
pharmaco-nutrient. In this commentary, we address
the impact of four studies that influenced the
recommendations on glutamine supplementation by
the Canadian Clinical Practice Guide 2015. Because of
the importance of this guideline in clinical practice,
we strongly believe that a more rigorous and critical
evaluation is required to support recommendations in
future guidelines.Quoting the current guidelines, the Critical CareGlutamine (Gln) is a highly abundant free amino acid
(AA) with multiple biological functions. It is also one of
the conditionally essential AAs, which means that its
levels are reduced in the body when under stress or in
hypercatabolic conditions [1]. Studies have identified pa-
tients in whom a depletion of Gln is correlated with
worsening of their pathological condition. Gln depletion
is also an independent predictor of mortality in intensive
care unit (ICU) patients [2, 3]. Moreover, Rodas et al.
[4] showed, in a small observational study, that low
(<400 μmol/l) and high (>930 μmol/l) plasma concentra-
tions of Gln in ICU patients are independent risk factors
for mortality. It has been reported that high Gln levels are
caused by acute liver failure [5] and that in kidney disease
the AA clearance is affected, increasing its plasmatic levelsCorrespondence: aaleguin@uc.cl
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with liver or kidney failure (or both) is contraindicated.
Owing to the limited solubility and instability of Gln
in aqueous solution [7], it has been supplemented to
total parenteral nutrition (TPN) in dipeptide alanylgluta-
mine form. Commonly used TPN products do not pro-
vide Gln in their basic composition.
International nutrition guidelines recommend Gln use
in ICU patients with TPN requirements. However, contro-
versy has emerged after the publication of the REDOX
(Reducing Deaths due to Oxidative Stress) study [8], caus-
ing distrust and fear in the use of this supplement.
Recently, a significant change in the guidelines for sup-
plementation of Gln was made by the 2015 Canadian
Clinical Practice Guidelines [9]. It is my view that this dis-
couragement of Gln use did not have strong justification.
Nutrition panel stated: “when parenteral nutrition is pre-
scribed to critically ill patients, we recommend paren-
teral supplementation with glutamine NOT be used.
There are insufficient data on the use of intravenous glu-
tamine in critically ill patients receiving enteral nutrition
but given the safety concerns we also recommend intra-
venous glutamine not be used in enterally fed critically
ill patients” [9].
This change in the 2013 guidelines was influenced by
the results of four new trials. The first one, by Carroll
et al. [10], is a small study (n = 12 per group) from 2004
that aimed to investigate the effect in anabolism of
growth hormone (GH) and insulin-like growth factor
(IGF) in the TPN with or without Gln in ICU patients.
Interestingly, the authors found that Gln supplementa-
tion caused a slight improvement in the net protein bal-
ance without any side effect, although no substantial
benefit was seen with GH or IGF. Furthermore, they ac-
knowledge the risk implied by the use of these anabolics
in TPN but report no evidence of changes in pivotalle is distributed under the terms of the Creative Commons Attribution 4.0
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or infection.
Secondly, Pérez-Bárcena et al. [11], in a more recent
report (2014), showed that suboptimal doses of Gln to
TPN for 5 days (with a start delay of more than 28 hours)
did not confer any benefit to the ICU patients. However,
plasmatic Gln measurement in the patients showed that
those with lower levels presented a worse outcome in
short-term mortality, LOS, and infections. Moreover, no
negative event was reported when Gln was supplemented.
Also in 2014, Grintescu et al. [12] showed that Gln
supplementation in trauma patients reduces hypergly-
cemic episodes and improves insulin response. The au-
thors suggest a role for Gln as an insulin sensitizer and
conclude that their results provide evidence for this.
Additionally, they highlight some exclusion parameters
used in their study (hepatic and kidney dysfunction) that
were not considered in the REDOX study.
In the final report which was considered, Koksal et al.
[13] in 2014 studied septic patients with a negative ni-
trogen balance. These patients received enteral nutrition
(EN) with or without intravenous (i.v.) Gln and with or
without enteral Gln. The authors’ main conclusion was
that a double Gln supplementation (i.v. + enteral) on
days 7 and 15 improved outcomes for septic patients
with malnutrition. Particular improvements were made
in transferrin, creatinine, and nitrogen balance. Even
when this study mixed TPN and EN with different Gln
supplementations, the Gln did not cause any side effects
or changes in the clinical outcomes of mortality, infec-
tions, or LOS.
From my point of view, four articles that led to
changes in the Canadian Nutrition Guidelines did not
actually report changes in clinical outcomes relevant to
Gln supplementation in TPN. Such outcomes include
mortality rates, LOS, and infections. None of the articles
reported any negative findings. I believe that even
though these well-designed studies give important clin-
ical evidence, a more rigorous and critical evaluation is
required to support appropriate decisions in future
guidelines.
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